Search Results

You are looking at 161 - 170 of 375 items for :

  • "therapeutics" x
  • Refine by Access: All x
Clear All
Full access

Multiple Myeloma: Advances Reported in 2013 Are Useful in the Clinic

Kenneth Anderson

of Medicine, Harvard Medical School, Director, LeBow Institute for Myeloma Therapeutics, Dana-Farber/Brigham and Women’s Cancer Center, Boston. Dr. Anderson chairs the NCCN Guidelines Panel for Multiple Myeloma, and he described the latest treatment

Full access

Delivering on the Promise of Patient-Centered Care

Patricia A. Ganz

behind “personalized” and “precision” approaches to cancer therapeutics. 2 In contrast, the concept of “patient-centered care” encompasses a broader swath of the cancer care delivery process in that before patients sign-on to a therapeutic approach for

Full access

Acting on Rare Driver Alterations: Is Getting a Meaningful Response a Game of Chance or Scientific Rigor?

David R. Braxton

driver alterations in general and especially uncommon cancer types. Still, it is becoming clear that achieving a meaningful clinical response from targeted therapeutics is increasingly a game of scientific rigor and less of chance. References 1

Full access

NCCN Guidelines Update for Multiple Myeloma

Kenneth C. Anderson

immune therapies will improve patient outcome even further,” Dr. Anderson concluded. Dr. Anderson has disclosed that he receives other financial benefit from Acetylon Pharmaceuticals, Inc.; C4 Therapeutics, Inc.; and OncoPep. He is a scientific

Full access

Major Changes in Systemic Therapy for Advanced Melanoma

John A. Thompson

.” Dr. Thompson has disclosed that he receives consulting fees and/or honoraria from Eisai Inc., Genentech, Inc., and Seattle Genetics; he receives other financial benefit from Celldex Therapeutics. References 1. Hodi FS O'Day SJ

Full access

Role of Dermatologists in Treating Melanoma

Allan C. Halpern and Sanjay K. Mandal

. Smalley KS Herlyn M . Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics . Ann N Y Acad Sci 2005 ; 1059 : 16 – 25 . 21. Bliss JM Ford D Swerdlow AJ . Risk of cutaneous melanoma associated with

Full access

Early Detection and Biomarkers in Pancreatic Cancer

David E. Misek, Tasneem H. Patwa, David M. Lubman, and Diane M. Simeone

therapeutics and diagnostics . Nat Rev Drug Discov 2005 ; 4 : 477 – 488 . 47. Orntoft TF Vestergaard EM . Clinical aspects of altered glycosylation of glycoproteins in cancer . Electrophoresis 1999 ; 20 : 362 – 371 . 48. Semmes OJ

Full access

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022

Featured Updates to the NCCN Guidelines

Natalie S. Callander, Muhamed Baljevic, Kehinde Adekola, Larry D. Anderson Jr, Erica Campagnaro, Jorge J. Castillo, Caitlin Costello, Srinivas Devarakonda, Noura Elsedawy, Matthew Faiman, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin Hultcrantz, Yubin Kang, Sarah Larson, Michaela Liedtke, Thomas Martin, James Omel, Douglas Sborov, Kenneth Shain, Keith Stockerl-Goldstein, Donna Weber, Ryan A. Berardi, Rashmi Kumar, and Shaji K. Kumar

., Amgen Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Pharmaceutica Products, LP, Karyopharm Therapeutics, Regeneron Pharmaceuticals, Inc., Roche Laboratories, Inc., Sanofi-aventis US, and Takeda Pharmaceuticals North America, Inc.; and has

Full access

The Costs of Drugs Used to Treat Myelodysplastic Syndromes Following National Comprehensive Cancer Network Guidelines

Peter L. Greenberg, Leon E. Cosler, Salvatore A. Ferro, and Gary H. Lyman

Dr. Greenberg is on the advisory board and a consultant for Celgene Corporation and Novartis AG, and receives research support from Celgene Corporation, Novartis AG, Amgen Inc., and GeminX. Dr. Cosler is a member of the Pharmacy & Therapeutics

Full access

NCCN Guidelines Updates: Management of Metastatic Kidney Cancer

Eric Jonasch

advisor for Genentech, Inc., Eisai Inc., Ipsen, and Peloton Therapeutics, Inc. References 1. Motzer RJ , Tannir NM , McDermott DF , Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma . N Eng J Med 2018 ; 378 : 1277